"Bioidentical hormones" is a source of persistent confusion because the term means different things to different people, and its use in marketing often diverges from its meaning in chemistry.

If you have looked into menopause treatment, you have likely encountered the phrase in the context of compounding pharmacies, wellness clinics, or practitioners presenting it as a natural alternative to conventional HRT. The implication is that bioidentical hormones are safer and more effective than what doctors typically prescribe. The evidence does not support this framing, and understanding why requires understanding what the word actually means.

What Bioidentical Actually Means

Bioidentical means the hormone molecule is structurally identical to the hormone produced by the human body. By this definition, 17β-estradiol is bioidentical: it is the same estrogen your ovaries made. Micronized progesterone is also bioidentical, being chemically identical to human progesterone in every respect.

Both molecules are available in FDA-approved, regulated pharmaceutical products. 17β-estradiol is the estrogen in standard patches, gels, sprays, and many tablets used in conventional HRT. Micronized progesterone is the active ingredient in Utrogestan and Prometrium.

Conjugated equine estrogen (used in the original Women's Health Initiative trial under the brand name Premarin) is derived from horse urine and is not bioidentical. Synthetic progestins like medroxyprogesterone acetate and norethisterone are not bioidentical either. To be clear: bioidentical does not mean compounded, and conventional does not mean non-bioidentical; these terms describe different things and should not be conflated.

The Compounding Confusion

The term "bioidentical hormones" has been largely co-opted by compounding pharmacies to describe their custom-prepared hormone mixtures. These are sold as superior to conventional HRT, with marketing that leans heavily on words like natural, individualised, and safer.

Compounded bioidentical hormone therapy (cBHT) refers to custom-prepared hormones mixed by a compounding pharmacy to a specific formulation, typically based on results from salivary or blood hormone testing. Products often include unusual combinations, such as estradiol, progesterone, testosterone, DHEA, and other hormones mixed into a single cream or troche.

The American College of Obstetricians and Gynecologists (ACOG) published a 2023 Clinical Consensus statement that is explicit on this point: FDA-approved menopausal hormone therapies should be recommended over compounded bioidentical menopausal hormone therapy, and patients should be counselled that evidence supporting the safety and effectiveness of cBHT is lacking.[1]

The FDA's position is equally clear: there is no evidence that compounded bioidentical hormones are safe and effective, or safer or more effective than FDA-approved hormone therapy.[2]

Problems With Compounded Preparations

Unpredictable dosing. Compounded products are not tested for consistency. A cream dispensed by a compounding pharmacy may contain substantially more or less hormone than labelled, and the daily dose absorbed can vary depending on application site, skin condition, and formulation stability. The FDA's adverse event reporting system contains cases of serious adverse events from excessive doses of estrogen, progesterone, and testosterone from compounded pellets specifically.[1]

No long-term safety data. The RCT evidence base for HRT comes almost entirely from FDA-approved products tested in large trials. These trials established both the benefits and the risks of HRT at specific doses. Compounded preparations have not been tested in comparable trials. Extrapolating the safety data from regulated products to compounded ones is not scientifically valid.

Hormone pellets carry specific risks. Subcutaneous pellets deposit a fixed amount of hormone that cannot be adjusted or removed once inserted. Because pellets release hormone continuously and unpredictably, they frequently produce supraphysiological levels. Women receiving pellet therapy often have testosterone and estradiol levels far above the premenopausal female range, which carries its own risk profile and produces effects (acne, voice changes) that most women seeking HRT do not want.

Salivary hormone testing does not reliably guide dosing. A common feature of cBHT protocols is testing saliva to determine hormone levels and personalise the formulation. Salivary hormone testing is not validated for clinical dosing decisions. Estradiol levels in saliva do not correlate reliably with serum levels, and results vary depending on collection time and technique.[3] NAMS and ACOG do not recommend salivary testing for guiding HRT dosing.

Choosing Bioidentical HRT

If you want bioidentical hormones (and there are legitimate reasons to prefer them, including the observed association between synthetic progestins and higher breast cancer risk, a relationship that is dose- and duration-dependent and remains an active area of debate, particularly across different progestin types[4]), FDA-approved bioidentical products give you exactly that, with regulatory quality control, pharmacovigilance data, and a meaningful evidence base behind them.

The standard prescription: transdermal 17β-estradiol (patch, gel, or spray) plus micronized progesterone (Utrogestan or Prometrium) for women who still have a uterus. This is what NICE, the British Menopause Society, and other current guidelines recommend as the preferred HRT formulation for most women.[4] It is also bioidentical by any technical definition. If you are uncertain which formulation is right for you, a qualified menopause specialist (rather than a compounding clinic) is the appropriate first stop.

The problems described above (unpredictable dosing, absent long-term trial data, and the specific hazards of pellet therapy) narrow the reasonable use of cBHT to a small set of specific situations. Compounded preparations are appropriate in specific, limited circumstances: when a woman cannot tolerate any approved formulation, needs a dose not available commercially, or has an allergy to an excipient in approved products. For the general population seeking menopause treatment, compounding adds cost and uncertainty without adding benefit.

References

[1] American College of Obstetricians and Gynecologists. (2023). Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6. https://pubmed.ncbi.nlm.nih.gov/37856860/

[2] US Food and Drug Administration. Menopause and hormones: common questions. https://www.fda.gov/media/130242/download

[3] Stanczyk, F. Z., Jurow, J., Hsing, A. W. (2010). Limitations of direct immunoassays for measuring circulating estradiol levels in postmenopausal women and their implications for epidemiologic studies. Cancer Epidemiology, Biomarkers & Prevention, 19(4), 903-906. Cited in: Bioidentical hormone therapy review. https://pmc.ncbi.nlm.nih.gov/articles/PMC3127562/

[4] NICE Guideline NG23. (2023). Menopause: Diagnosis and Management. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng23